Fig. 2: Ikaros binding sites at ARID5B promoter in B-ALL cells were determined by ChIP-seq (a). | Oncogenesis

Fig. 2: Ikaros binding sites at ARID5B promoter in B-ALL cells were determined by ChIP-seq (a).

From: Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia

Fig. 2

b, c Ikaros binding at ARID5B promoter was validated by qChIP assay in b ALL cell lines and (c) primary ALL cells. Graphed data are the mean ± SD of triplicates representative of one of 3 independent experiments (a, b) or 3 patient samples (c). ***p < 0.001

Back to article page